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trast to the findings of Melo and col-
leagues,1 and despite the younger age of
our patients, we found no significant dif-
ference in the incidence of AF between the
two well-matched groups in our study.
Melo and colleagues1 failed to come up
with a convincing reason for the claimed
effectiveness of the technique. Anatomi-
cally, the route taken by autonomic nerves
to the heart is highly variable2; a lesser but
significant and variable proportion of auto-
nomic nerves reaches the heart along the
pulmonary veins and the back of the heart,
so the actual denervation achieved in quan-
titative terms is not consistent or compara-
ble between patients unless the innervation
is mapped out before denervation. The in-
clusion of patients with diabetes (26% in
the VCD group and 27% in the control
group in their study and 16% and 13%,
respectively, in our own study) and patients
receiving -blockers (75% in the VCD
group and 81% in the control group in their
study and 69% and 72%, respectively, in
our study) gives rise to additional prob-
lems. Many patients with diabetes already
have partial denervation from preexisting
autonomic neuropathy, and it is debatable
how much additional denervation is
achieved surgically with the technique.
-Blockers themselves have antiarrhyth-
mic effects and produce a state of near-total
pharmacologic sympathetic denervation.
Long-term -blockade causes -receptor
hypersensitivity, necessitating reintroduc-
tion of -blockers after the operation. The
reintroduction of -blockers in most cases
in the postoperative period results in total
cardiac sympathetic denervation and partial
parasympathetic denervation, which raises
questions about the whole hypothesis.
One can only meaningfully assess the
effectiveness of the technique through a
prospective, randomized multicenter trial
excluding patients with diabetes and those
receiving -blockers. Histologic quantifi-
cation of the amount and type of nerve
fibrils in the excised fat pads is also neces-
sary.
Joseph Alex, MBBS, MRCS
Mazhar Ur Rehman, MBBS, FRCS (CTh)
Levent Guvendik, MD, FRCS, FETCS
Department of Cardiothoracic Surgery
Castle Hill Hospital
Hull And East Yorkshire Hospitals NHS Trust
Hull, United Kingdom
References
1. Melo J, Voigt P, Sonmez B, Ferreira M, Abe-
casis M, Robocho M, et al. Ventral cardiac
denervation reduces the incidence of atrial
fibrillation after coronary artery bypass graft-
ing. J Thorac Cardiovasc Surg. 2004;127:
511-5.
2. Pauza D, Skripa V, Pauzienne N, Stropus R.
Morphology, distribution and variability of
the epicardial neural subplexus in the human
heart. Anat Rec. 2000;259:353-82.
doi:10.1016j.jtcvs.2004.03.044
Use of enoxaparin in cardiac surgery
To the Editor:
We congratulate Dr Medalion and cowork-
ers1 for the results reported in their study
recently published in the Journal that fo-
cused on the effects of enoxaparin in pa-
tients undergoing coronary operations. The
optimal administration of low-molecular-
weight heparin in cardiac surgery is a con-
troversial issue.2,3 The use of enoxaparin in
patients with prosthetic valves has also
been recently described.4,5 Because we
have routinely used enoxaparin both pre-
operatively and postoperatively in non-
emergency cardiac patients at our institu-
tion during the last 5 years, we would like
to outline some aspects of our experience.
When we started using enoxaparin in
1998, we had some concerns related to the
potential bleeding hazards. Although we
never measured anti-factor Xa activity, we
did not experience any major bleeding
complications that could primarily be re-
lated to the use of enoxaparin itself, and we
gradually developed a simplified protocol
(Table 1), which is, however, significantly
different from the one described. Doses of
preoperative enoxaparin are much lower,
and antiplatelet therapy is stopped on ad-
mission. On the other hand, a low dose of
enoxaparin is given to all patients awaiting
surgical intervention once daily (twice
daily if the dose exceeds 4000 U/d). Also,
patients who could potentially be stabilized
with higher doses of enoxaparin and treated
on an urgent basis, typically patients with
coexistent left main disease and unstable
angina, are instead treated as emergency
cases and, as such, receive unfractionated
heparin infusion until transfer to the oper-
ating room. Enoxaparin is also used after
surgical intervention to minimize thrombo-
embolic complications until a satisfactory
international normalized ratio is attained in
patients receiving oral anticoagulation and
to prevent deep venous thrombosis.
In the study cited above,1 although it is
clear that patients classified as emergency
cases receive heparin infusion, the authors
do not specify when to administer subcu-
taneous enoxaparin versus intravenous
heparin in urgent cases. The level of anti-
coagulation and the laboratory tests used
(eg, partial thromboplastin time and acti-
vated clotting time) in patients receiving
intravenous heparin are also not reported,
and this might influence the measurements
of anti-factor Xa activity at skin incision.
Although results might be biased by a spe-
cial accuracy in surgical hemostasis in pa-
tients enrolled in the study, bleeding rates
were low in all subgroups despite high
doses of enoxaparin (1 mg/kg twice daily),
TABLE 1. Use of enoxaparin before and after cardiac operations
Variable Dose
Preoperative course
Standard minimal dose 2000 U
Minimal dose in patients with atrial fibrillation or
oral anticoagulation
4000 U
Maximal dose 2  4000 U
Conditions that modify preoperative doses
Intravenous nitrates or left main stenosis 50% 2  dose
Endocarditis or cardiac neoplasm 2  dose
Body mass index 30 2  dose
Body mass index 25 1/2 dose
Ticlopidine or clopidogrel withdrawal 1/2 dose
Hemoglobin 12 g/dL 1/2 dose
Postoperative course
Standard dose 2000 U until mobilization
Oral anticoagulation or atrial fibrillation 4000 U until INR 2
Body mass index 30 4000 U until mobilization
One hundred units of enoxaparin  1 mg.
INR, International normalized ratio.
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administration of enoxaparin late until sur-
gical intervention (8.7  0.75 hours preop-
eratively), and nonwithdrawal of aspirin.
In conclusion, we agree with the au-
thors that the use of enoxaparin before rou-
tine cardiac operations appears safe as far
as major bleeding complications are con-
cerned. Probably this consideration also
applies to the early postoperative period; in
this respect administration of high-dose
enoxaparin (1 mg/kg twice daily) has re-
cently been reported after mechanical valve
implantation as a bridge to satisfactory oral
anticoagulation.5 Finally, higher doses
might be justified in some subsets of criti-
cally ill patients undergoing coronary op-
erations, although a clear cutoff indication
between subcutanous enoxaparin versus
heparin infusion remains to be elucidated.
In our opinion caution is advised because
the benefits of high-dose enoxaparin might
be outweighed by the risks related to a less
aggressive attitude toward unstable patients
awaiting coronary bypass surgery.
Marco Pocar, MD, PhD
Alessio Assaghi, MD
Francesco Donatelli, MD
Cattedra di Cardiochirurgia
Universita` degli Studi di Milano
Policlinico MultiMedica
Milan, Italy
References
1. Medalion B, Frenkel G, Patachenko P,
Hauptman E, Sasson L, Schachner A. Preop-
erative use of enoxaparin is not a risk factor
for postoperative bleeding after coronary ar-
tery bypass surgery. J Thorac Cardiovasc
Surg. 2003;126:1875-9.
2. Kincaid EH, Monroe ML, Saliba DL, Kon
ND, Byerly WG, Reichert MG. Effects of
preoperative enoxaparin versus unfraction-
ated heparin on bleeding indices in patients
undergoing coronary artery bypass grafting.
Ann Thorac Surg. 2003;76:124-8.
3. Jones HU, Muhlestein JB, Jones KW, Bair
TL, Lavasani F, Sohrevardi M, et al. Preop-
erative use of enoxaparin compared with un-
fractionated heparin increases the incidence
of re-exploration for postoperative bleeding
after open-heart surgery in patients who
present with an acute coronary syndrome:
clinical investigation and reports. Circula-
tion. 2002;106(suppl I):I19-22.
4. Ferreira I, Dos L, Tornos P, Nicolau I, Per-
manyer-Miralda G, Soler-Soler J. Experience
with enoxaparin in patients with mechanical
heart valves who must withhold acenocum-
arol. Heart. 2003;89:527-30.
5. Fanikos J, Tsilimingras K, Kucher N, Rosen
AB, Hieblinger MD, Goldhaber SZ. Compar-
ison of efficacy, safety, and cost of low-mo-
lecular-weight heparin with continuous-infu-
sion unfractionated heparin for initiation of
anticoagulation after mechanical prosthetic
valve implantation. Am J Cardiol. 2004;93:
247-50.
doi:10.1016/j.jtcvs.2004.02.043
Reconstruction of double-outlet right
ventricular outflow tract comprising
a pulmonary artery flap in a child
with an anomalous coronary artery
To the Editor:
van Son1 provided a useful operative solu-
tion for repairing tetralogy of Fallot of
anomalous origin in the left anterior de-
scending coronary artery and small pulmo-
nary annulus. The technique, using a pul-
monary artery flap as the posterior wall of
the constructed pathway, has the potential
advantage of preserving growth and avoid-
ing coronary damage for this subset. How-
ever, no interim or long-term results have
been reported.
A 3-year-old boy who had been cya-
notic since birth because of a double-outlet
right ventricle with a subaortic ventricular
defect and infundibular-valvular pulmo-
nary stenosis (z value2 of 3.6) underwent
a definitive operation according to the in-
structions of the proposed technique at our
institute. The right coronary artery origi-
nated from the aorta, transversing the right
ventricular outflow tract (RVOT) very near
the main pulmonary trunk because of l-
transpositioned great arteries. Seven years
postoperatively, the pressure gradient
across the RVOT had increased to 80 mm
Hg from 20 mm Hg, even though the native
pulmonary valve annulus and a patchy re-
constructed tract orifice had grown by 11
mm (z  2.8) and 15.5 mm (z  1.2),
respectively (Figure 1). Meanwhile, the
right coronary artery beneath the con-
structed pathway showed no distortion.
The growth of the RVOT without harm-
ful influence on the coronary artery was
proved in this case, and the problem in-
volved in leaving the native outflow tract
open was elucidated. The anatomic steno-
sis advanced concomitant with develop-
ment of the native pathway. The blood-
streams from both pathways probably
created turbulence at the merging point,
making the outflow tract bulge centrifu-
gally. The dilated native posterior wall rose
up and protruded into the pathway as a
transverse fold. Although we still support
the early definitive repair of Fallot-type
cyanotic disease, we conclude that com-
Figure 1. A, Angiogram 4 years postoperatively: the right ventricular angiogram demonstrates the development of
reconstructed and native pathways. B, Angiogram 7 years postoperatively: the native outflow tract bulged
centrifugally, and the posterior wall protruded into the pulmonary outflow tract as a transverse fold (black arrows)
with a pressure gradient of 80 mm Hg.
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